Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings

American Journal of Cardiovascular Drugs

Volumn 14, Issue 6, 2014, Pages 451-462

  Verhoef, Talitha I ^a,b   Redekop, William K ^c   Hasrat, Fazila ^a   de Boer, Anthonius ^a   Maitland van der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; COUMARIN ANTICOAGULANT; DABIGATRAN; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; COUMARIN DERIVATIVE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ANALYTIC METHOD; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG COST; EMBOLISM; EUROPEAN; HEALTH CARE QUALITY; HEALTH STATUS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART INFARCTION PREVENTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; NETHERLANDS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TRANSIENT ISCHEMIC ATTACK; UNITED KINGDOM; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROBABILITY; STROKE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST-BENEFIT ANALYSIS; COUMARINS; DABIGATRAN; GREAT BRITAIN; HUMANS; MARKOV CHAINS; MIDDLE AGED; MORPHOLINES; NETHERLANDS; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; RIVAROXABAN; STROKE; THIOPHENES;

EID: 84914818609     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-014-0092-1     Document Type: Article

References (58)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67.
2. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160s–98s. doi:10.1378/chest.08-0670.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med. 2009;361(12):1139–51. doi:10.1056/NEJMoa0905561.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Eng J Med. 2010;363(19):1875–6. doi:10.1056/NEJMc1007378.
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Eng J Med. 2011;365(11):981–92. doi:10.1056/NEJMoa1107039.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Eng J Med. 2011;365(10):883–91. doi:10.1056/NEJMoa1009638.
7. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110(3):453–60. doi:10.1016/j.amjcard.2012.03.049.
8. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145(1):105–12.e15. doi:10.1053/j.gastro.2013.02.041.
9. Kansal AR, Zheng Y, Pokora T, Sorensen SV. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Pract Res Clin Haematol. 2013;26(2):225–37. doi:10.1016/j.beha.2013.07.012.
10. Limone BL, Baker WL, Kluger J, Coleman CI. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PloS One. 2013;8(4):e62183. doi:10.1371/journal.pone.0062183.
11. Verhoef TI, Redekop WK, van Schie RM, Bayat S, Daly AK, Geitona M, et al. Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics. 2012;13(12):1405–17. doi:10.2217/pgs.12.124.
12. Federation of Dutch Anticoagulant clinics. Samenvatting medische jaarverslagen 2011. http://www.fnt.nl/media/docs/jaarverslagen/Medisch_Jaarverslag_FNT_2011.pdf. Accessed 11 Aug 2014.
13. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess (Winch Eng). 2007;11(38):3–4 (9–66).
14. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106(5):968–77. doi:10.1160/th11-05-0353.
15. Schalekamp T, de Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr Pharm Design. 2010;16(2):187–203.
16. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120(8):700–5. doi:10.1016/j.amjmed.2006.07.034.
17. Bernheim SM, Grady JN, Lin Z, Wang Y, Wang Y, Savage SV, et al. National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes. 2010;3(5):459–67. doi:10.1161/circoutcomes.110.957613.
18. Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009;2(5):407–13. doi:10.1161/circoutcomes.109.883256.
19. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 2010;28(1):61–74. doi:10.2165/11318240-000000000-00000.
20. Centraal bureau voor de statistiek, life tables. http://statline.cbs.nl/statweb/. Accessed 11 Aug 2014.
21. Office of National Statistics, life tables. http://www.statistics.gov.uk/. Accessed 11 Aug 2014.
22. World Health Organization,Global Health Observatory Data Repository. http://apps.who.int/gho/data/?vid=710#.
23. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91.
24. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ. 2008;179(3):235–44. doi:10.1503/cmaj.080171.
25. O’Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293(6):699–706. doi:10.1001/jama.293.6.699.
26. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123(22):2562–70. doi:10.1161/circulationaha.110.985655.
27. Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S, et al. Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost. 2012;10(4):606–14. doi:10.1111/j.1538-7836.2012.04633.x.
28. Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021–33.
29. Jowett S, Bryan S, Mahe I, Brieger D, Carlsson J, Kartman B, et al. A multinational investigation of time and traveling costs in attending anticoagulation clinics. Value Health. 2008;11(2):207–12. doi:10.1111/j.1524-4733.2007.00253.x.
30. Dutch healthcare authority. Beleidsregel voor trombosediensten. http://www.nza.nl/137706/145406/623721/BR-CU-2083-Trombosediensten.pdf. Accessed 15 May 2014.
31. National Institute of Health and Clinical Excellence. Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. NICE technology appraisal guidance 275. 2013. http://www.nice.org.uk/nicemedia/live/14086/62874/62874.pdf. Accessed 15 May 2014.
32. Dutch drug costs. Available from: http://www.medicijnkosten.nl.
33. International society for pharmacoeconomics and outcomes research.
34. Hakkaart-van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Instituut voor Medical Technology Assessment, Erasmus Universiteit Rotterdam, in opdracht van het College voor Zorgverzekeringen. 2010.
35. National Institute of Health and Clinical Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. Final appraisal determination. 2011. http://www.nice.org.uk/nicemedia/live/12225/56899/56899.pdf. Accessed 15 May 2014.
36. Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Future costs of stroke in The Netherlands: the impact of stroke services. Int J Technol Assess Health Care. 2006;22(4):518–24. doi:10.1017/s0266462306051464.
37. Luengo-Fernandez R, Yiin GS, Gray AM, Rothwell PM. Population-based study of acute- and long-term care costs after stroke in patients with AF. Int J Stroke. 2013;8(5):308–14. doi:10.1111/j.1747-4949.2012.00812.x.
38. Buisman LR, Tan SS, Koudstaal PJ, Nederkoorn PJ, Redekop WK. Hospital costs of ischemic stroke and transient ischemic attack in The Netherlands. ISPOR 17th Annual European Congress to be held 8–12 November 2014 at the Amsterdam RAI, Amsterdam, The Netherlands.
39. Department of Health. NHS Trusts and PCTs combined reference cost schedules 2010–11. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_131148.xls. Accessed 15 May 2014.
40. Dutch healthcare authority. NZa. DBC-tariefapplicatie. 2011. http://dbc-tarieven.nza.nl/Nzatarieven/top.do.
41. Greving JP, Visseren FL, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ (Clin Res Ed). 2011;342:d1672. doi:10.1136/bmj.d1672.
42. Roos YB, Dijkgraaf MG, Albrecht KW, Beenen LF, Groen RJ, de Haan RJ, et al. Direct costs of modern treatment of aneurysmal subarachnoid hemorrhage in the first year after diagnosis. Stroke J Cereb Circ. 2002;33(6):1595–9.
43. Schalekamp T, Boink GJ, Visser LE, Stricker BH, de Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther. 2006;79(6):511–20. doi:10.1016/j.clpt.2006.03.008.
44. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437–52. doi:10.1002/hec.864.
45. Stolk EA, van Donselaar G, Brouwer WB, Busschbach JJ. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics. 2004;22(17):1097–107.
46. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ (Clin Res Ed). 2011;343:d6333. doi:10.1136/bmj.d6333.
47. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 2012;98(7):573–8. doi:10.1136/heartjnl-2011-300646.
48. Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, et al. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. 2013;31(7):551–62. doi:10.1007/s40273-013-0051-8.
49. Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35(28):1897-906. doi:10.1093/eurheartj/ehu006.
50. Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, et al. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013;6(6):724–31. doi:10.1161/circoutcomes.113.000661.
51. Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, et al. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 2013;16(4):498–506. doi:10.1016/j.jval.2013.01.009.
52. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke J Cereb Circ. 2013;44(6):1676–81. doi:10.1161/strokeaha.111.000402.
53. Krejczy M, Harenberg J, Marx S, Obermann K, Frolich L, Wehling M. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. J Thromb Thrombolysis. 2014;37(4):507–23. doi:10.1007/s11239-013-0989-6.
54. Lanitis T, Cotte FE, Gaudin AF, Kachaner I, Kongnakorn T, Durand-Zaleski I. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin. J Med Econ. 2014;17(8):587-98. doi:10.3111/13696998.2014.923891.
55. Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig. 2014;34(1):9–17. doi:10.1007/s40261-013-0144-3.
56. Wisloff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014;32(6):601–12. doi:10.1007/s40273-014-0152-z.
57. Pink J, Pirmohamed M, Lane S, Hughes DA. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation. Clin Pharmacol Ther. 2014;95(2):199–207. doi:10.1038/clpt.2013.190.
58. Pengo V, Pegoraro C, Cucchini U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis. 2006;21(1):73–7. doi:10.1007/s11239-006-5580-y.